Background
==========

Gastric cancer (GC) is the fourth most common malignancy and the second-leading cause of cancer-related death worldwide \[[@b1-medscimonit-21-1911]\]. Lymph node metastasis is one of the most important prognostic factors for survival after curative gastrectomy \[[@b2-medscimonit-21-1911]\]. However, many patients have node-negative disease on their pathologic examination. Nonetheless, data on survival of surgical resection patients with node-negative GC, as well as predictors of prognosis, are relatively limited \[[@b3-medscimonit-21-1911]--[@b9-medscimonit-21-1911]\]. Most available studies were conducted in a single institution and included small groups of patients. Therefore, we performed the present systematic review to evaluate survival and identify prognostic factors in node-negative GC patients undergoing curative intent resection.

Material and Methods
====================

Systematic search strategy
--------------------------

Using PubMed database, a systematic review was made of all peer-reviewed English-language papers published between January 2000 and January 2015 that reported patient survival after gastrectomy of node-negative GC. The following Medical Subject Headings terms were used: "gastric cancer," "node negative," or "lymph-node negative". The reference lists of retrieved articles were reviewed for additional citations.

Criteria for inclusion and exclusion
------------------------------------

Studies reporting the results of 5-year overall survival (OS) and disease-free survival (DFS) of node-negative GC patients undergoing curative-intent resection were included. Studies that focused on molecular markers, abstracts, editorials, expert opinions, animal studies, and studies with fewer than 100 patients were excluded.

Data abstraction and quality assessment
---------------------------------------

Data regarding the following variables were extracted from each article by 2 authors (Yanming Zhou and Feng Yu) independently: first author, year of publication, study period, sample size, study population characteristics, and outcomes of interests. The quality of articles was assessed using the Newcastle-Ottawa Scale \[[@b10-medscimonit-21-1911]\]. Discrepancies between the 2 reviewers were resolved by discussion and consensus.

Statistical analysis
--------------------

Data are presented as median (range) unless otherwise stated. Risk estimates from univariate analysis or multivariate estimating survival were obtained from each study and meta-analyzed for the prognostic factors using a random-effects model. The pooled estimates for variables are reported as relative risks (RR) with 95% confidence interval (95% CI). If a study contained subgroups of GC (such as stages) and consequently multiple RR, the individual RR were combined to yield an overall RR and used in the final meta-analysis. Statistical significance was set at *P*\<0.05. All analyses were performed using the Review Manager (RevMan) software, version 5.1 (The Cochrane Collaboration, Software Update, Oxford).

Results
=======

A total of 30 publications with 31 reports met the inclusion criteria and were included for analysis. The characteristics of the patients included in the analyzed studies are summarized in [Table 1](#t1-medscimonit-21-1911){ref-type="table"} \[[@b3-medscimonit-21-1911]--[@b9-medscimonit-21-1911],[@b11-medscimonit-21-1911]--[@b33-medscimonit-21-1911]\]. All studies were retrospective. Most reports originated from Asia (Japan, n=5; China, n=9; Korea, n=7; and other, n=3), followed by Europe (n =4) and the United States (n =3). These papers described 12504 patients. There were 8585 (68.6%) men and 3919 (31.4%) women. The median age ranged from 53 to 69.1 years. The median number of nodes examined ranged from 10.3 to 39.3.

The median follow-up period ranged from 36.5 to 124.6 months among the studies analyzed. Five-year OS was reported in all 31 reports with a median value of 84.3% (range, 53--96.3%). [Table 2](#t2-medscimonit-21-1911){ref-type="table"} demonstrates the survival rates stratified by patient subgroups.

Results of the meta-analysis are shown in [Table 3](#t3-medscimonit-21-1911){ref-type="table"}. Old age, \<D2 lymph node dissection, larger tumor, serosal invasion, and vessel invasion were found to be significantly associated with poor OS ([Figures 1](#f1-medscimonit-21-1911){ref-type="fig"}[](#f2-medscimonit-21-1911){ref-type="fig"}[](#f3-medscimonit-21-1911){ref-type="fig"}[](#f4-medscimonit-21-1911){ref-type="fig"}--[5](#f5-medscimonit-21-1911){ref-type="fig"}). In contrast, tumor location, histology and adjuvant chemotherapy did not affect survival significantly.

Five-year DFS was reported in 4 studies with a median value of 77.7% (range, 57.3--96.3%) \[[@b14-medscimonit-21-1911],[@b19-medscimonit-21-1911],[@b28-medscimonit-21-1911],[@b30-medscimonit-21-1911]\]. We did not further analyze prognostic factors due to the small number of trials and relatively small patient samples.

Discussion
==========

Surgical resection is the treatment of choice for node-negative GC patients. The median 5-year OS is 84.3% ranging from 53% to 96.3%. The discrepancy may be due to the variation in patient population, surgical experience on the part of the surgeon, and postoperative care at different centers.

Despite generally favorable therapeutic outcomes for node-negative GC, a subset of these patients may still have relatively poor outcomes, and therefore identification of prognostic factors may have important implications to postoperative surveillance and adjuvant therapy in these patients.

Old age is found to be associated with a poor outcome. The difference in survival between elderly and younger patients could in part be explained by the more limited survival expectancy of the elderly population, and also reflected by the higher prevalence of co-morbidity.

Tumor-related factors, including serosal invasion, larger tumor size, and vessel invasion, seem to have most prognostic significance. Serosal invasion increases tumor contact with surrounding organs or likelihood of peritoneal seeding. The high incidence of hematogenous dissemination in patients with a larger tumor size may explain the association between the larger tumor size and the poor outcome \[[@b25-medscimonit-21-1911]\]. Node-negative GC with lymphatic and vascular invasion indicates a more aggressive disease. Growing evidence indicates that tumor lymphangiogenesis and angiogenesis play important roles in the progression of GC \[[@b34-medscimonit-21-1911]\]. In addition, high lymphatic vessel density and microvessel density are shown to be correlated with a poor survival rate in human GC \[[@b35-medscimonit-21-1911]\]. Therefore, other than lymphovascular invasion of tumor cells as an important prognostic factor in GC, targeting tumor-associated lymphangiogenesis and angiogenesis may also provide a novel therapeutic approach. Vascular endothelial growth factor (VEGF)-A and VEGF-C are 2 important molecules involved in GC development and metastasis by promoting angiogenesis and lymphangiogenesis. It has been shown that blocking angiogenesis and lymphangiogenesis can suppresses GC growth markedly in an experimental setting \[[@b36-medscimonit-21-1911]\]. Bevacizumab, a recombinant humanized version of a murine monoclonal antibody for VEGF, is an important component of treatment for metastatic colorectal cancer \[[@b37-medscimonit-21-1911]\]. In a phase 3 trial of patients with advanced GC, although the addition of bevacizumab to capecitabine-cisplatin did not significantly improve overall survival, it resulted in improved progression-free survival and overall response rate \[[@b38-medscimonit-21-1911]\].

During dissemination of tumor cells to lymph nodes, lymphatic vessels provide a direct pathway for metastasis, and this pathway is often activated at an early stage in the metastatic process. Lymphatic invasion has previously been observed as a risk factor for micrometastasis in patients with node-negative GC \[[@b39-medscimonit-21-1911]\]. As expected, extended lymphadenectomy (D2 or greater) may be more efficient than D1 lymphadenectomy in removing micrometastic foci, thus offering a survival advantage, as shown in the present meta-analysis. With the disease progressing, the likelihood of lymphatic invasion and micrometastasis increases, thus making it more likely that an extended lymphadenectomy would be associated with an improved outcome by stage \[[@b8-medscimonit-21-1911]\].

We found that adjuvant therapy after resection did not provide a significant survival benefit for node-negative GC patients. This was consistent with the result of 1 large-scale phase III clinical trial, which showed adjuvant chemotherapy (oxaliplatin and capecitabine) did not significantly improve the 3-year disease-free survival for node-negative GC \[[@b40-medscimonit-21-1911]\]. However, only 103 node-negative GC patients were enrolled in this study. The small sample size may have been insufficient to evaluate differences between the groups, and therefore further research is needed.

This analysis is limited by the heterogeneity of the studies included. There are no internationally accepted scaled definitions for old age or large tumor in GC surgery. The definition of elderly patients in the included reports varied from 58, 60, and 65 years \[[@b3-medscimonit-21-1911],[@b4-medscimonit-21-1911],[@b6-medscimonit-21-1911],[@b7-medscimonit-21-1911],[@b9-medscimonit-21-1911],[@b13-medscimonit-21-1911],[@b16-medscimonit-21-1911],[@b18-medscimonit-21-1911],[@b20-medscimonit-21-1911]--[@b25-medscimonit-21-1911],[@b28-medscimonit-21-1911]--[@b30-medscimonit-21-1911]\]. Similarly, the definition of large tumor varied from 3, 4, 4.75, 5, 6.3, and 7 cm \[[@b4-medscimonit-21-1911],[@b7-medscimonit-21-1911],[@b9-medscimonit-21-1911],[@b13-medscimonit-21-1911],[@b15-medscimonit-21-1911],[@b17-medscimonit-21-1911],[@b18-medscimonit-21-1911],[@b20-medscimonit-21-1911],[@b21-medscimonit-21-1911],[@b23-medscimonit-21-1911]--[@b30-medscimonit-21-1911],[@b33-medscimonit-21-1911]\]. On the other hand, some authors did not specify the criteria at all \[[@b22-medscimonit-21-1911] [@b27-medscimonit-21-1911]\]. The interobserver variability may have caused detection bias. In addition, compared with advanced GC, early GC has less aggressive biological features and a more favorable prognosis. As most included studies did not perform independent assessment in this aspect, we were unable to analyze prognostic factors stratified by tumor stage. It is also important to note that variables of interest were not uniformly available from each study. Due to limited data, we did not analyze the prognostic significance of gross appearance (Borrmann type), Lauren classification, perineural invasion, and type of gastrectomy. Finally, some studies using immunohistochemical staining combining cytokeratin and vascular markers including CD31 and CD34 reported that D2--40 was more sensitive than standardized H&E alone in detecting lymphatic and vascular invasion \[[@b30-medscimonit-21-1911]\]. However, lymphovascular invasion was evaluated by H&E staining alone in most centers. Thus, the clinical importance of these variables was underestimated.

Conclusions
===========

The present analysis demonstrates that surgical resection offers a good OS for patients with node-negative GC. Tumor-related factors including tumor size and vascular invasion seem to have most prognostic significance.

We thank Doctor Yanfang Zhao (Department of Health Statistics, Second Military Medical University, Shanghai, China) for her critical revision of the statistical analysis section.

**Disclosure of interest**

The authors declare that they have no conflicts of interest concerning this article.

**Source of support:** Departmental sources

![Result of the meta-analysis on old age.](medscimonit-21-1911-g001){#f1-medscimonit-21-1911}

![Result of the meta-analysis on D1 lymphadenectomy.](medscimonit-21-1911-g002){#f2-medscimonit-21-1911}

![Result of the meta-analysis on larger tumor.](medscimonit-21-1911-g003){#f3-medscimonit-21-1911}

![Result of the meta-analysis on serosal invasion.](medscimonit-21-1911-g004){#f4-medscimonit-21-1911}

![Result of the meta-analysis on vessel invasion.](medscimonit-21-1911-g005){#f5-medscimonit-21-1911}

###### 

Clinical background of included studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference (year)                                 Period of inclusions   Country   N      M/F       Age (years)a   T stage\   TS (cm)[\*](#tfn2-medscimonit-21-1911){ref-type="table-fn"}   LND \<D2/≥D2   NNE[\*](#tfn2-medscimonit-21-1911){ref-type="table-fn"}   OM (%)   FU (months)   5-year OS (%)
                                                                                                                    T1/≥T2                                                                                                                                                                   
  ------------------------------------------------ ---------------------- --------- ------ --------- -------------- ---------- ------------------------------------------------------------- -------------- --------------------------------------------------------- -------- ------------- ---------------
  Bruno (2000) \[[@b3-medscimonit-21-1911]\]       1986--1998             Italy     130    81/49     67             63/37      --                                                            100/30         17.4                                                      --       48.7          72

  Hyung (2002) \[[@b4-medscimonit-21-1911]\]       1993--1996             Korea     280    196/84    ≥60, n=112     0/280      ≥4.0, n=168                                                   --             39.3                                                      --       74            78.9

  Kooby (2003) \[[@b5-medscimonit-21-1911]\]       1985--2001             USA       465    286/179   67             188/277    3                                                             114/333        23                                                        --       36.5          79

  Kim (2006) \[[@b6-medscimonit-21-1911]\]         1986--2000             Korea     1524   988/536   56.9           804/720    2.9                                                           262/1262       --                                                        --       --            77.4

  Kunisaki (2006) \[[@b7-medscimonit-21-1911]\]    1975--1997             Japan     733    500/233   58.3           507/226    3.5                                                           182/551        36.8                                                      --       66.9          87.3

  Park (2006) \[[@b8-medscimonit-21-1911]\]        1993--2000             Korea     506    337/169   55.2           347/159    2.9                                                           32/474         33.7                                                      --       69.8          90.3

  Lee (2007) \[[@b9-medscimonit-21-1911]\]         1988--1999             Taiwan    384    296/88    \>65, n=228    301b/83    ≥4.0, n=140                                                   --             --                                                        --       60.4          91.7

  Deng (2008) \[[@b11-medscimonit-21-1911]\]       1997--2000             China     112    70/42     54.2           --         --                                                            37/75          --                                                        0        84            85.7

  Otsuji (2008) \[[@b12-medscimonit-21-1911]\]     1970--2001             Japan     221    143/78    59             0/221      5.3                                                           28/193         --                                                        1.8      --            77.1

  Ichikawa (2009) \[[@b13-medscimonit-21-1911]\]   1974--2006             Japan     828    560/268   60.9           651/177    3.6                                                           --             --                                                        --       --            94.3

  Baiocchi (2010) \[[@b14-medscimonit-21-1911]\]   1992--2002             Italy     301    171/130   69.1           0/301      4.36                                                          0/301          29.8                                                      1.7      124.6         73.7

  Saito (2010) \[[@b15-medscimonit-21-1911]\]      1975--2000             Japan     277    169/108   60.9           0/277      6.1                                                           21/256         --                                                        --       --            84.9

  Biffi (2011) \[[@b16-medscimonit-21-1911]\]      2000--2005             Italy     114    67/47     63             52/59      --                                                            0/114          22                                                        0        76            92.1

  Cao (2011) \[[@b17-medscimonit-21-1911]\]        2000--2005             China     160    103/57    --             160/0      --                                                            --             10.3                                                      --       68            85

  Qiu (2011) \[[@b18-medscimonit-21-1911]\]        2003--2008             China     222    157/65    58             26/196     4                                                             --             26.3                                                      --       58.3          73

  Seshadri (2011) \[[@b19-medscimonit-21-1911]\]   1991--2007             Indian    121    86/35     53             22/99      \>3, n=85                                                     23/98          22                                                        --       58            68.2

  Jeong (2012) \[[@b20-medscimonit-21-1911]\]      1992--2010             Korea     967    643/324   ≥60, n=414     728/239    ≥5, n=256                                                     --             --                                                        --       60            89.5

  Liu (2012) \[[@b21-medscimonit-21-1911]\]        1996--2007             China     234    158/76    56             67/167     3.4a                                                          0/234          21.1                                                      --       51.8          85

  Sun (2012) \[[@b22-medscimonit-21-1911]\]        1995--2001             China     458    336/122   56.7           0/458      --                                                            30/428         24.6                                                      --       69.7          62

  Wang (2012) \[[@b23-medscimonit-21-1911]\]       2001--2005             China     153    104/49    59             57/96      3.4                                                           0/153          23                                                        --       69            77.3

  Xu (2012) \[[@b24-medscimonit-21-1911]\]         1992--2006             China     435    293/142   56             97/338     \>5, n=147                                                    0/435          13.5                                                      --       72            78.4

  Chou (2013) \[[@b25-medscimonit-21-1911]\]       1994--2006             Taiwan    448    297/151   62.8           0/448      3.7                                                           --             25.9                                                      Ex       78.7          84.3

  Lee (2013) \[[@b26-medscimonit-21-1911]\]        2003--2005             Korea     424    283/141   58             0/424      4.8a                                                          0/424          27                                                        0        63            92

  Song (2013) \[[@b27-medscimonit-21-1911]\]       1995--2005             Korea     598    404/194   58             598/0      2.0                                                           96/502         --                                                        0.3      68.4          96.3

  Strong (2013) \[[@b27-medscimonit-21-1911]\]     1995--2005             USA       159    90/69     69             148/--     1.8                                                           39/119         --                                                        1        68.4          88.0

  Araki (2014) \[[@b28-medscimonit-21-1911]\]      2000--2010             Japan     130    98/32     65.5           0/130      5.0                                                           --             --                                                        --       59            89

  Jiao (2014) \[[@b29-medscimonit-21-1911]\]       2000--2008             China     497    365/132   \>60, n=246    34/463     \>4, n=245                                                    --             13.8                                                      Ex       --            67.2

  Xu (2014) \[[@b30-medscimonit-21-1911]\]         1995--2008             China     492    381/111   ≥60, n=237     158/234    3.79                                                          --             --                                                        --       --            81.9

  Dittmar (2015) \[[@b31-medscimonit-21-1911]\]    1994--2011             Germany   228    144/84    63             --         --                                                            --             --                                                        Ex       59            83

  Lee (2015) \[[@b32-medscimonit-21-1911]\]        2001--2010             Korea     586    398/188   57             471/15     --                                                            28/558         34                                                        --       74.9          92

  Jin (2015) \[[@b33-medscimonit-21-1911]\]        2000--2012             USA       317    176/141   66             143/174    3.5                                                           139/178        17                                                        Ex       68            53
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

M -- male; F -- female; TS -- tumor size; LND -- lymph node dissection; NNE -- number of nodes evaluated; FU -- follow-up; OM -- operative mortality; Ex -- excluded; OS -- overall survival;

mean or median.

###### 

Summary of 5-year overall survival stratified by patient subgroups.

  Patient group                        5-year overall survival Median (range)   No. of studies
  ------------------------------------ ---------------------------------------- ----------------
  All patients                         84.3% (62--96.3%)                        29
  Sex                                                                           14
   Male                                84% (66--94.2%)                          
   Female                              84.7% (58--97%)                          
  Age (years)                                                                   13
   Old                                 79.4% (64.2--93.1%)                      
   Young                               89.3% (65.1--96%)                        
  Lymph node dissection                                                         6
   \<D2                                74.3% (63--88.2%)                        
   ≥D2                                 82.3% (73.2--91.5%)                      
  Tumor size                                                                    14
   Larger                              71.8% (48.7--91.4%)                      
   Smaller                             88.8% (71--97%)                          
  Location                                                                      
   Upper                               83.4% (34.8--93.3%)                      12
   Middle                              85% (53.2--95.8%)                        12
   Lower                               86.5% (62.3--3.4%)                       12
   Whole                               61.4% (25--70%)                          5
  T stage                                                                       
   T1                                  93% (85--97%)                            13
   T2                                  84% (69.5--90.9%)                        9
   T3                                  77.7% (52--77.9%)                        8
   T4                                  61.9% (40--71.2%)                        4
  Histologic grade                                                              11
   Well or moderately differentiated   88.6% (66.2--94.9%)                      
   Poorly or undifferentiated          81.7% (65.8--94.4%)                      
  Lymphatic invasion                                                            6
   Absent                              89.9% (86.5--97.1%)                      
   Present                             70.1% (50--89%)                          
  Vascular invasion                                                             6
   Absent                              89.2% (86.8--93%)                        
   Present                             79.1% (52--83%)                          
  Lymphovascular invasion                                                       4
   Absent                              87.5% (74.1--98.1%)                      
   Present                             73% (40--91.6%)                          
  Adjuvant chemotherapy                                                         4
   Yes                                 75.8% (69.8--80%)                        
   No                                  81.8% (30.8--91%)                        

###### 

Summary of the results of the meta-analysis.

  Prognostic factor            Risk ratio   95% CI       P-value   No. of studies
  ---------------------------- ------------ ------------ --------- ----------------
  Old age                      1.26         1.13, 1.42   \<0.001   18
  Male sex                     1.01         0.97, 1.06   0.58      22
  \<D2 lymph node dissection   1.28         1.05, 1.55   0.01      6
  Location (upper)             0.96         0.91, 1.02   0.15      18
  Larger tumor size            1.18         1.10, 1.26   \<0.001   20
  Serosal invasion (T3)        2.03         1.68, 2.44   \<0.001   17
  Undifferentiated tumor       1.05         0.99, 1.12   0.08      19
  Lymphatic invasion           1.25         1.00, 1.57   0.05      8
  Vascular invasion            1.67         1.19, 2.34   0.003     7
  Lymphovascular invasion      1.93         1.20, 3.10   0.007     6
  Adjuvant chemotherapy        1.02         0.84, 1.25   0.84      5
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